Dyslipidemia in renal disease

Seminars in Nephrology

Volumn 16, Issue 3, 1996, Pages 202-213

  Mittman, Neal ^a,b,c   Avram, Morrell M ^a,b  

^a Division of Nephrology   (United States)

^b LONG ISLAND COLLEGE HOSPITAL   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; COLESTIPOL; COLESTYRAMINE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

ATHEROSCLEROSIS; DIET THERAPY; DYSLIPIDEMIA; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MALNUTRITION; MORTALITY; NEPHROTIC SYNDROME; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UREMIA; VASCULAR ACCESS;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES; LIPIDS; LIPOPROTEIN(A); NUTRITION DISORDERS; RENAL DIALYSIS;

EID: 0029876395     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Virchow R: A more precise account of fatty metamorphosis, in Chance F (ed): Cellular Pathology. Gryphonham, Gryphon Editions, 1860, pp 324-366
2. Diamond JR, Karnovsky MJ: A putative role of hypercholesterolemia in progressive glomerular injury. Annu Rev Med 43:83-92, 1992
3. Grone EF, Walli AK, Grone HJ, et al: The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 107:1-13, 1994
4. Moorhead JF, El-Nahas M, Chan MK, et al: Lipid neph-rotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 1:1309-1311, 1982
5. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis: A model analagous to atherosclerosis. Am J Nephrol 8:261-271, 1988
6. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 33:917-924, 1988
7. Schlondorff D: Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 22:72-82, 1993
8. Neugarten J, Schlondorff D: Lipoprotein interactions with glomerular cells and matrix, in Keane WF, Stein JH (eds): Lipids and Renal Disease, Contemporary Issues in Nephrology. New York, NY, Churchill Livingstone, 1991, pp 173-205
9. Avram MM: Low-density lipoprotein immunofluorescence at the site of renal injury in glomerulosclerosis: A potential pathogenetic role for lipids in renal disease. Am J Kidney Dis 22:69-71, 1993
10. Pesek-Diamond I, Ding OH, Frye J, et al: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 263:F776-F783, 1992
11. Kasiske BL, O'Donnell MP, Schmitz PG, et al: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 37:880-891, 1990
12. O'Donnell MP, Kasiske BL, Katz SA, et al: Lovastatin but not enalapril reduces glomerular injury in Dahl-sensitive rats. Hypertension 20:651-658, 1992
13. Tolins JP, Stone BJ, Raij L: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. Kidney Int 41:1254-1261, 1992
14. Keane WF, Mulcahy WS, Kasiske BL, et al: Hyperlipidemia and progressive renal disease. Kidney Int 39:S41-S48, 1991
15. Manske CL: Lipid abnormalities and renal disease. Kidney 20:25-30, 1988
16. Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 19:625-637, 1981
17. Cutler RE: Lipid disorders in renal disease: Prevalence, pathogenesis and diagnosis. Dial Transplant 17:533-536, 1988
18. Riesen WF, Mordasini R: Hyperlipidemia in renal failure: Phenotypes and pathogenic mechanisms. Contrib Nephrol 41:312-320, 1984
19. Kuo PT, Busset DR: Dietary sugar in the production of hypertriglyceridemia. Ann Intern Med 62:1199-1212, 1965
20. Attman PO, Alaupovic P, Gustafson A: Serum apolipoproteins of patients with chronic renal failure. Kidney Int 32:368-375, 1987
21. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein remnant formation in chronic renal failure. N Engl J Med 307:329-333, 1982
22. Tatami R, Hiroshi M, Kosei K, et al: Intermediate-density lipoprotein and cholesterol-rich very-low-density lipoprotein in angiographically-determined coronary artery disease. Circulation 64:1174-1184, 1981
23. Goldberg AP, Applebaum-Bowden DM, Bierman EL, et al: Increase in lipoprotein lipase activity during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301:1073-1076, 1979
24. Chan MK, Persaud J, Varghese Z, et al: Pathogenic roles of post-heparin upases in lipid abnormalities in hemodialysis patients. Kidney Int 25:812-818, 1984
25. Arnadottir M, Thysell H, Dallangeville J, et al: Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 48:779-784, 1995
26. Akmal M, Kasim SE, Soliman AR, et al: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 37:854-858, 1990
27. Arnadottir M, Nilsson-Ehle P: Parathyroid hormone is not an inhibitor of lipoprotein lipase activity. Nephrol Dial Transplant 9:1586-1589, 1994
28. Green D, Stone NJ, Krumlovsky FA: Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovasc Dis 26:133-144, 1983
29. Sasaki J, Cottam GL: Glycosylation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochem Biophys Acta 713:199-207, 1982
30. Ozawa K, Goto K, Kijama Y, et al: The effect of CAPD on lipid abnormalities detected by apoproteins and ultracentrifugal lipid subfractions, in Maher J, Winchester JF (eds): Frontiers in Peritoneal Dialysis. New York, NY, Field, Rich and Assoc., 1986, pp 432-436
31. Lundin AP, Adler AJ, Feinroth MV, et al: Maintenance hemodialysis: Survival beyond the first decade. JAMA 244:38-40, 1980
32. Lindner A, Charra B, Sherrard DJ, et al: Accelerated atherosclerosis on prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1974
33. Lowrie ED, Lazarus JM, Mocelin AJ, et al: Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 288:863-867, 1973
34. Rostand SG, Gretes JC, Kirk KA, et al: Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 16:600-611, 1979
35. Rostand SG, Kirk KA, Rutsky EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22:304-308, 1982
36. Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 25:653-659, 1984
37. Goldberg AP, Harter HR, Patsch W, et al: Racial differences in plasmahigh-density lipoproteins in patients receiving hemodialysis. N Engl J Med 308:1245-1252, 1983
38. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end-stage renal disease-difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 77:1071-1083, 1986
39. Bagdade JD, Albers JJ: Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med 296:1436-1439, 1977
40. Chan MK, Persaud J, Varghese Z, et al: Pathogenic roles of post-heparin upases in lipid abnormalities in hemodialysis patients. Kidney Int 25:812-818, 1984
41. Ponticelli C, Barbi G, Cataluppi A, et al: Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int 13:572-578, 1978
42. Ibels LS, Simons LA, King JO, et al: Studies on the nature and causes of hyperlipidemia in uremia, maintenance dialysis, and renal transplantation. Q J Med 44:601-614, 1975
43. Avram MM, Fein PA, Antignani A, et al: Cholesterol and lipid disturbances in renal disease: The natural history of the uremic dyslipidemia and the impact of hemodialysis and peritoneal dialysis. Am J Med 87:55N-60N, 1989
44. Avram MM, Goldwasser P, Burrell DE, et al: The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 20:324-335, 1992
45. Lacour B, Roullet JB, Beyne P, et al: Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients. J Clin Chem Biochem 23:805-810, 1985
46. Ramos JM, Heaton A, McGurk JG, et al: Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 35:20-23, 1983
47. Lindholm B, Norbeck HE: Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 220:143-151, 1986
48. Kagan A, Bar-Khayim Y, Schafer Z, et al: Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 37:980-990, 1990
49. Kagan A, Bar-Khayim Y, Schafer Z, et al: Heterogeneity in peritoneal transport during continuous ambulatory peritoneal dialysis and its impact on Ultrafiltration, loss of macromolecules and plasma level of proteins, lipids and lipoproteins. Nephron 63:32-42, 1993
50. Utermann G, Duba C, Menzel HJ: Genetics of the quantitative Lp(a) lipoprotein trait. I. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 78:37-50, 1988
51. Zioncheck TF, Powell LM, Rice GC, et al: Interactions of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 87:767-771, 1991
52. Parra HJ, Mezdour H, Cachera C, et al: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 33:721, 1987
53. Cressman MD, Heyka RJ, Paganini EP, et al: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
54. Morisett JD, Guyton JR, Gaubatz JW, et al: Lipoprotein(a): Structure, metabolism, and epidemiology, in Grotto AM (ed): Plasma Lipoproteins. Amsterdam, Elsevier Science, 1987, pp 129-152
55. McLean JW, Tomlinson JE, Kuang WJ, et al: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137, 1987
56. Loscalzo J, Weinfeld M, Fless GM, et al: Lipoprotein(a), fibrin binding, and plasminogen activation. Arterioscler Thromb 10:240-245, 1990
57. Goldwasser P, Michel MA, Collier J, et al: Prealbumin and lipoprotein(a) in hemodialysis: Relationship with patient and vascular access survival. Am J Kidney Dis 21:215-225, 1993
58. Murphy BG, McNamee P, Duly E, et al: Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis 93:53-57, 1992
59. Karadi I, Romics L, Palos G, et al: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origins. Clin Chem 35:2121-2123, 1988
60. Thomas ME, Freestone A, Varghese Z, et al: Lipoprotein(a) in patients with proteinuria. Nephrol Dial Transplant 7:597-601, 1992
61. Faucher C, Doucet C, Baumelou A, et al: Elevated lipoprotein(a) levels in primary nephrotic syndrome. Am J Kidney Dis 22:808-813, 1993
62. Murai A, Miyahara T, Fujimoto N, et al: Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 59:199-204, 1986
63. Dahlen GH, Guyton JR, Attar M, et al: Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary disease documented by angiography. Circulation 74:758-765, 1986
64. Scanu A: Lipoprotein(a): A genetic risk factor for premature coronary disease. JAMA 267:3326-3329, 1992
65. Rosengren A, Wilhelmsen L, Eriksson E, et al: Lipoprotein(a) and coronary heart disease: A prospective case control study in a general population sample of middle aged men. Br Med J 301:1248-1251, 1990
66. Hoff HF, Beck GJ, Skibinski CI, et al: Serum Lp(a) level as a predictor of vein graft stenosis after coronary bypass surgery in patients. Circulation 77:1238-1244, 1988
67. Guyton JR, Dahlen GH, Ratsch W, et al: Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 5:265-272, 1985
68. Srinivasan SR, Dahlen GH, Jarpa RA, et al: Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Circulation 84:160-167, 1991
69. Haire HM, Sherrard DJ, Scardapane D, et al: Smoking, hypertension, and mortality in a maintenance dialysis population. Cardiovasc Med 7:1163-1168, 1978
70. Hahn R, Oette K, Mondorf H, et al: Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48:279-288, 1983 (abstr)
71. Gurland HJ, Brunner FP, Dehn H, et al: Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc 10:10-21, 1978
72. Ibels LS, Alfrey AC, Huffer WE, et al: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66:790-796, 1979
73. Burke JF, Francos GC, Moore LL, et al: Accelerated atherosclerosis in chronic dialysis patients-Another look. Nephron 21:181-185, 1978
74. Nicholls AJ, Edward N, Catto GRD, et al: Accelerated atherosclerosis in long-term dialysis and renal transplantation: Fact or fiction? Lancet 1:276-278, 1980
75. Lundin AP, Friedman EA: Vascular consequences of maintenance hemodialysis-An unproven case. Nephron 21:177-180, 1978
76. Bergesio F, Ciuti R, Salvadori M, et al: Are lipid abnormalities reliable cardiovascular risk factors in dialysis patients? Int J Artif Organs 12:677-682, 1989
77. Parsy D, Dracon M, Cachera C, et al: Lipoprotein abnormalities in chronic hemodialysis patients. Dial Transplant 3:51-56, 1988
78. Hutchinson TA, Thomas DC, MacGibbon B: Predicting survival in adults with end-stage renal disease: An age equivalence index. Ann Intern Med 96:417-423, 1982
79. Maiorca R, Vonesh E, Cancarini GC, et al: A six-year comparison of patient and technique survivals in CAPD and HD. Kidney Int 34:518-524, 1988
80. Silberberg JS, Barre PE, Prichard SS, et al: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:268-290, 1989
81. Grutzmacher P, Marz W, Peschke B, et al: Lipoproteins and apolipoproteins during progression of chronic renal disease. Nephron 50:103-111, 1988
82. Ritz E, Augustin J, Bommer J, et al: Should hyperlipidemia of renal failure be treated? Kidney Int S17:584-587, 1985
83. Avram MM, Mittman N, Bonomint L, et al: Markers for survival in dialysis: A seven-year prospective study. Am J Kidney Dis 26:209-219, 1995
84. Markell MS, Butt KMH, Brown CD, et al: Renal transplant patients who develop early hyperlipidemia have different post-transplant patterns of lipid profiles than those who do not. Transplant Proc 21:1497-1499, 1989
85. Kasiske BL, Umen AJ: Persistent hyperlipidemia in renal transplant patients. Medicine 66:309-316, 1987
86. Nichols J, Cumming AM, Catto GRD, et al: Lipid relationships in dialysis and renal transplant patients. Q J Med 198:149-160, 1981
87. Cattran DC, Steiner G, Wilson DR, et al: Hyperlipidemia after renal transplantation: Natural history and pathophysiology. Ann Intern Med 91:554-559, 1979
88. Ibels LS, Alfrey AC, Weil R: Hyperlipidemia in adult, pediatric, and diabetic renal transplant recipients. Am J Med 64:634-642, 1978
89. Harris KPG, Russel GI, Parvin SD, et al: Alterations in lipid and carbohydrate metabolism attributable to cyclosporine A in renal transplant recipients. Br Med J 292:16, 1986
90. Steinmuller TM, Graf KJ, Schleicher J, et al: The effect of FK506 versus cyclosporine on glucose and lipid metabolism - A randomized trial. Transplantation 58:663, 1994
91. Vatsala A, Weinberg RB, Schoenberg L, et al: Lipid abnormalities in cyclosporine-prednisone treated renal transplant recipients. Transplantation 48:37-43, 1989
92. Raine AEG, Carter R, Mann JI, et al: Increased plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression. Transplant Proc 19:1820-1821, 1987
93. Verslius DJ, Wenting GJ, Derkx FHM, et al: Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why. Transplantation 44:387-389, 1987
94. Shen SY, Lukens CW, Alongi SV, et al: Patient profile and effect of dietary therapy on post-transplant hyperlipidemia. Kidney Int 24:S147-S152, 1983
95. Segarra A, Chacon P, Martin M, et al: Serum lipoprotein(a) levels in patients with chronic renal failure-Evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: A prospective study. Nephron 69:9-13, 1995
96. Gault MH, Longerich LL, Purchase L, et al: Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 70:155-170, 1995
97. Black JW, Wilcken DE: Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 38:353-357, 1992
98. Appel GB, Blum CB, Chien S, et al: The hyperlipidemia of the nephrotic syndrome. N Engl J Med 312:1544-1548, 1985
99. Short CD, Durrington PN, Mallick NP, et al: Serum and urinary high-density lipoproteins in glomerular disease with proteinuria. Kidney Int 29:1224-1228, 1986
100. Joven J, Villabona C, Vilella E, et al: Abnormalities of lipoprotein metabolism in patients with nephrotic syndrome. N Engl J Med 323:579-584, 1990
101. Cameron JS: The nephrotic syndrome and its complications. Am J Kidney Dis 10:157-171, 1987
102. Marsh JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25:1619-1623, 1984
103. Garber DW, Gottlieb BA, Marsh JB, et al: Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74:1375-1383, 1984
104. Vega GL, Toto RD, Grundy SM: Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 47:579, 1995
105. Appel G: Nephrology Forum: Lipid abnormalities in renal disease. Kidney Int 39:169-183, 1991
106. Baxter JH, Goodman HC, Havel FJ: Serum lipid and lipoprotein alterations in nephrosis. J Clin Invest 39:455-465, 1960
107. Wass VJ, Jarrett RJ, Chilvers C, et al: Does the nephrotic syndrome increfce the risk of cardiovascular disease? Lancet 2:664-667, 1979
108. Wass V, Cameron JS: Cardiovascular disease and the nephrotic syndrome: The other side of the coin. Nephron 27:58-61, 1981
109. Alexander JH, Schapel GJ, Edwards KD: Increased incidence of coronary heart disease associated with combined elevation of serum triglycerides and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 2:119-122, 1974
110. Berlyne GM, Mallick NP: Ischaemic heart disease as a complication of the nephrotic syndrome. Lancet 2:399-400, 1969
111. Ordonez JD, Hiatt R, Killebrew FJ, et al: The increased risk of coronary heart disease associated with the nephrotic syndrome. Kidney Int 44:638-642, 1993
112. Appel GB, Valeri A, Appel AS, et al: The hyperlipidemia of the nephrotic syndrome. Am J Med 87:45N-51N, 1989
113. Sanfilippo ML, Swenson RS, Reaven GM: Reduction of plasma triglycerides by diet in subjects with chronic renal failure. Kidney Int 14:180-186, 1978
114. D'Amico G, Gentile MG: Influence of diet on lipid abnormalities in human renal disease. Am J Kidney Dis 22:151-157, 1993
115. Witztum JL, Dillingham MA, Giese W, et al: Normalization of triglycerides in Type IV hyperlipoproteinemia fails to correct low levels of high-density lipoprotein cholesterol. N Engl J Med 303:907-914, 1980
116. Goldberg AP, Hagberg JM, Delmez JA, et al: Metabolic effects of exercise training in hemodialysis patients. Kidney Int 18:754-761, 1980
117. Hamazaki T, Nakazawa R, Tateno S, et al: Effects of fish oil rich in eicosapentanoic acid on serum lipid in hyperlipidemic hemodialysis patients. Kidney Int 26:81-84, 1984
118. Massy ZA, Ma JZ, Louis TA, et al: Lipid-lowering therapy in patients with renal disease. Kidney Int 48: 188-198, 1995
119. Valeri A, Gelfand J, Blurn C, et al: Treatment of hyperlipidemia of the nephrotic syndrome. Am J Kidney Dis 8:388-396, 1986
120. Rabelink AJ, Erkelens DW, Hene RJ, et al: Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidemia of nephrotic syndrome. Lancet 2:1335-1338, 1988
121. Ida H, Izumino K, Asaka M, et al: Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. Nephron 47:280-283, 1987
122. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med 317:1237-1245, 1987
123. Groggel GF, Cheung AK, Ellis-Benigni K, et al: Safe and effective treatment of the hyperlipidemia of nephrotic syndrome with gemfibrozil. Kidney Int 36:266-271, 1989
124. Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33:1160-1168, 1988
125. Golper TA, Illingworth DR, Morris CD, et al: Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 8:312-320, 1989
126. Spitalewitz S, Porush JG, Cattran D, et al: Treatment of hyperlipidemia in the nephrotic syndrome: The effect of pravastatin therapy. Am J Kidney Dis 22:143-150, 1993
127. Brown CD, Azrolan N, Thomas L, et al: Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. Am J Kidney Dis 26:170-177, 1995
128. Keilani T, Schleuter WA, Levin ML, et al: Improvement of lipid abnormalities associated with proteinuria using fosenopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118:246, 1993
129. Gansevoort RT, Heeg JE, Dikkeschei FD, et al: Symptomatic antiproteinuric treatment decreases serum Lp(a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 9:244, 1994
130. Bosch T, Thiery J, Samtleben W, et al: Combined simultaneous LDL-apheresis and hemodialysis in hypercholesterolemic ESRD patients: A new mode of therapy. J Am Soc Nephrol 2:233, 1991 (abstr)
131. Nakahama H, Miyazaki M, Imai N, et al: Reduction of plasma lipoprotein(a) levels by niceritrol in patients on maintenance hemodialysis. J Am Soc Nephrol 2:340, 1991 (abstr)
132. Gokal R, Mann JI, Oliver DO, et al: Treatment of hyperlipidaemia in patients on chronic haemodialysis. Br Med J 276:82-83, 1978 (abstr)
133. World Health Organization: W.H.O. Cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: Mortality follow-up. Lancet 1:380-385, 1980
134. Vacha GM, Giorcelli G, Siliprandi N, et al: Favorable effects of L-camitine treatment on hypertriglyceridemia in hemodialysis patients: Decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr 38:532-540, 1983
135. Pollock CA, Wyndham R, Collett PV, et al: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 45:897-902, 1994
136. Seres DS, Strain GW, Hashim SA, et al: Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 3:1409-1415, 1993
137. Docci D, Capponcini C, Mengozzi S, et al: Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients. Nephron 69:323-326, 1995
138. Jung K, Scheifler A, Schulze BD, et al: Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate. Am J Kidney Dis 25:584-588, 1995
139. Nelson J, Beauregard H, Gelinas M, et al: Rapid improvement of hyperlipidemia in kidney transplant patients with multifactorial hypolipidemic diet. Transplant Proc 20:1264-1270, 1988
140. Curtis JJ, Galla JH, Woodford SY, et al: Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 22:42-47, 1982
141. Drukker A, Turner C, Start K, et al: Hyperlipidemia after renal transplantation in children on alternate day corticosteroid therapy. Clin Nephrol 26:140-145, 1986
142. Hricik DE: Posttransplant hyperlipidemia: The treatment dilemma. Am J Kidney Dis 23:766, 1994
143. Avram MM, Klahr S: Introduction: Lipids, hypertension, and nutrition in renal disease. Am J Kidney Dis 26:88-90, 1995
144. Avram MM, Mittman N: Malnutrition in uremia. Semin Nephrol 14:238-244, 1994